title: A novel therapy for myasthenia gravis by reducing the endocytosis of acetylcholine receptors.
authors.affiliation: Department of Neurology, Johns Hopkins University School of Medicine, Baltimore, Maryland 21205.
authors.forename: R W
authors.initials: RW
authors.lastname: Kuncl
authors.forename: I
authors.initials: I
authors.lastname: Wittstein
authors.forename: R N
authors.initials: RN
authors.lastname: Adams
authors.forename: W W
authors.initials: WW
authors.lastname: Wiggins
authors.forename: O
authors.initials: O
authors.lastname: Avila
authors.forename: A
authors.initials: A
authors.lastname: Pestronk
authors.forename: K
authors.initials: K
authors.lastname: McIntosh
authors.forename: D
authors.initials: D
authors.lastname: Lucas
authors.forename: S
authors.initials: S
authors.lastname: DeSilva
authors.forename: M
authors.initials: M
authors.lastname: Lehar
mesh_terms: D000818:Animals; D015536:Down-Regulation / Q000187:drug effects; D004705:Endocytosis / Q000187:drug effects; D005260:Female; D007114:Immunization; D007116:Immunization, Passive; D051379:Mice; D009157:Myasthenia Gravis / Q000188:drug therapy*; D051381:Rats; D011917:Rats, Inbred Lew; D011978:Receptors, Nicotinic / Q000378:metabolism*; D014372:Tubercidin / Q000494:pharmacology
chemical_list: D011978:Receptors, Nicotinic; C018258:3-deazaadenosine; D014372:Tubercidin